Salix Pharmaceuticals, Ltd. Share Price

Stocks

17/03/15	Endo : Valeant trumps Endo with $10.96 billion bid for Salix Pharma	RE
16/03/15	Bank of Montreal : TSX climbs on upbeat sentiment ahead of Fed meeting	RE
16/03/15	Wall St. bounces as dollar drops, Fed worries ease	RE
16/03/15	Endo : withdraws offer for Salix	RE
11/03/15	Valeant Pharmaceuticals Intl : TSX rebounds as energy shares advance with oil price	RE
05/03/15	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
05/03/15	AbbVie : Biotech buys get pharma M&A off to flying start in 2015	RE
05/03/15	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
24/02/15	Shire : buys Meritage Pharma for at least $70 million	RE
23/02/15	Canadian Natural Resources : TSX gains on Valeant news; financial stocks weigh	RE
23/02/15	Boeing : Nasdaq ends up 9th session; S&P 500, Dow dip with energy	RE
23/02/15	BioMarin Pharmaceutical : Exclusive - Rare disease drugmaker PTC Therapeutics explores sale: sources	RE
21/02/15	Salix Pharmaceuticals : Valeant nears deal to buy Salix for about $10 billion - WSJ	RE

11/03/15	Salix Pharmaceuticals : Confirms Receipt of an Unsolicited Proposal from Endo International plc	BU
02/03/15	Salix Pharmaceuticals : Reports 4Q2014 and FY2014 Results	BU
28/02/15	Salix Pharmaceuticals : SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Salix Pharmaceuticals, Ltd. And Encourages Investors To Contact The Firm For Additional Information	BU
27/02/15	Salix Pharmaceuticals : Stockholders Encouraged to Contact Securities Law Firm about Takeover	PR
26/02/15	SALIX PHARMACEUTICALS : SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout	BU

01/04/15	Valeant Pharmaceuticals Intl : Le laboratoire canadien Valeant conclut l'acquisition de Salix
30/03/15	Sanofi ne juge pas des acquisitions "indispensables"-Pdt
16/03/15	Le recul du dollar a favorisé le rebond de Wall Street
16/03/15	Allergan : Valeant relève son offre sur Salix, Endo jette l'éponge
16/03/15	BlackBerry : Les valeurs à suivre sur les marchés américains

Manager	Title	Age	Since
Josh Coyle SAM	Sales & Marketing	-	31/12/2017
John Temperato SAM	Sales & Marketing	61	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SALIX PHARMACEUTICALS, LTD.	-.--%	+0.16%	-	-	0
MERCK & CO., INC.	-1.29%	-2.34%	+58.21%	+19.85%	317B
MERCK KGAA	-0.07%	+1.50%	+38.91%	-9.22%	72.72B
HALOZYME THERAPEUTICS, INC.	+14.90%	+18.57%	+57.60%	+132.97%	10.17B
KYOWA KIRIN CO., LTD.	+1.29%	-0.31%	-5.23%	-4.32%	8.31B
SK BIOPHARMACEUTICALS CO., LTD.	+1.83%	+7.60%	-17.73%	-13.29%	4.6B
YUHAN CORPORATION	+3.60%	+5.14%	-32.05%	+11.14%	4.08B
BETTA PHARMACEUTICALS CO., LTD.	+3.02%	+10.06%	-11.26%	+24.85%	3.83B
SUPERNUS PHARMACEUTICALS, INC.	+0.16%	+4.41%	+12.40%	+44.50%	2.72B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-3.27%	-2.97%	-5.09%	-6.49%	2.16B
Average	+2.01%	+1.71%	+10.64%	+22.22%	47.29B
Weighted average by Cap.	-0.52%	-0.39%	+50.73%	+16.74%

Employees

Sector